Ascelia Pharma AB (publ)

OM:ACE Stock Report

Market Cap: SEK 280.6m

Ascelia Pharma Future Growth

Future criteria checks 6/6

Ascelia Pharma is forecast to grow earnings and revenue by 47.2% and 76.2% per annum respectively. EPS is expected to grow by 71.3% per annum. Return on equity is forecast to be 31.5% in 3 years.

Key information

47.2%

Earnings growth rate

71.3%

EPS growth rate

Biotechs earnings growth44.5%
Revenue growth rate76.2%
Future return on equity31.5%
Analyst coverage

Low

Last updated09 Nov 2024

Recent future growth updates

Recent updates

Health Check: How Prudently Does Ascelia Pharma (STO:ACE) Use Debt?

Nov 09
Health Check: How Prudently Does Ascelia Pharma (STO:ACE) Use Debt?

Is Ascelia Pharma (STO:ACE) Using Debt In A Risky Way?

May 31
Is Ascelia Pharma (STO:ACE) Using Debt In A Risky Way?

Is Ascelia Pharma (STO:ACE) In A Good Position To Invest In Growth?

May 11
Is Ascelia Pharma (STO:ACE) In A Good Position To Invest In Growth?

Ascelia Pharma (STO:ACE) Is In A Good Position To Deliver On Growth Plans

Aug 05
Ascelia Pharma (STO:ACE) Is In A Good Position To Deliver On Growth Plans

We Think Ascelia Pharma (STO:ACE) Can Afford To Drive Business Growth

Jan 24
We Think Ascelia Pharma (STO:ACE) Can Afford To Drive Business Growth

We Think Ascelia Pharma (STO:ACE) Can Afford To Drive Business Growth

Aug 23
We Think Ascelia Pharma (STO:ACE) Can Afford To Drive Business Growth

Companies Like Ascelia Pharma (STO:ACE) Are In A Position To Invest In Growth

May 19
Companies Like Ascelia Pharma (STO:ACE) Are In A Position To Invest In Growth

Here's What Ascelia Pharma AB (publ)'s (STO:ACE) Shareholder Ownership Structure Looks Like

Mar 07
Here's What Ascelia Pharma AB (publ)'s (STO:ACE) Shareholder Ownership Structure Looks Like

Helena Wennerström Is The Independent Director of Ascelia Pharma AB (publ) (STO:ACE) And They Just Picked Up 125% More Shares

Dec 09
Helena Wennerström Is The Independent Director of Ascelia Pharma AB (publ) (STO:ACE) And They Just Picked Up 125% More Shares

We Think Ascelia Pharma (STO:ACE) Can Afford To Drive Business Growth

Nov 26
We Think Ascelia Pharma (STO:ACE) Can Afford To Drive Business Growth

Earnings and Revenue Growth Forecasts

OM:ACE - Analysts future estimates and past financials data (SEK Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202612-60-49-492
12/31/202542-13-22-192
12/31/2024N/A-65-53-522
9/30/2024N/A-62-60-60N/A
6/30/2024N/A-62-74-74N/A
3/31/2024N/A-89-104-104N/A
12/31/2023N/A-109-127-127N/A
9/30/2023N/A-152-140-140N/A
6/30/2023N/A-157-141-141N/A
3/31/2023N/A-139-131-131N/A
12/31/2022N/A-131-125-125N/A
9/30/2022N/A-113-129-129N/A
6/30/2022N/A-115-127-127N/A
3/31/2022N/A-126-125-125N/A
12/31/2021N/A-126-117-117N/A
9/30/2021N/A-127-112-112N/A
6/30/2021N/A-113-100-100N/A
3/31/2021N/A-111-90-90N/A
12/31/2020N/A-99-86-86N/A
9/30/2020N/A-90-75-75N/A
6/30/2020N/A-88-76-76N/A
3/31/2020N/A-71-70-70N/A
12/31/2019N/A-66-54-54N/A
9/30/2019N/A-46-47-47N/A
6/30/2019N/A-37-30-30N/A
3/31/2019N/A-30-19-19N/A
12/31/2018N/A-23-19-19N/A
9/30/2018N/A-22-17-17N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ACE is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.2%).

Earnings vs Market: ACE is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ACE is expected to become profitable in the next 3 years.

Revenue vs Market: ACE's revenue (76.2% per year) is forecast to grow faster than the Swedish market (1.2% per year).

High Growth Revenue: ACE's revenue (76.2% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: ACE's Return on Equity is forecast to be high in 3 years time (31.5%)

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/30 05:34
End of Day Share Price 2024/12/30 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Ascelia Pharma AB (publ) is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Lars HevrengDanske Bank
Ludvig SvenssonPenser Access
Johan UnnerusRedeye